Brian Freeman, MD
Medical Oncology · Des Moines, IANPI 1225141609
Payments from drug & device makers
What this record shows
This record is dominated by education: $12 of the $12 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Gilead. That places this record below the midpoint for medical oncology clinicians in IA, where the typical reported total is $879.
Across 1 payment — averaging $11.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$12
Across 6 payments — averaging $26,799 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$161K
What the payments were for
- Education$12100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 1 | $12 |
How this compares
$12 in reported general payments places this provider in the 5th percentile of 47 medical oncology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 31 | $710,810 |
| Lenalidomide | 46 | $623,069 |
| ImbruvicaIbrutinib | 36 | $554,003 |
| RevlimidLenalidomide | 32 | $540,194 |
| CalquenceAcalabrutinib Maleate | 25 | $311,868 |
| PromactaEltrombopag Olamine | 11 | $217,473 |
| BrukinsaZanubrutinib | 14 | $210,440 |
| VenclextaVenetoclax | 17 | $146,069 |
| Deferasirox | 21 | $59,603 |
| Abiraterone Acetate | 44 | $40,368 |
| Enoxaparin Sodium | 29 | $16,815 |
| EliquisApixaban | 23 | $13,314 |
| Anastrozole | 146 | $2,290 |
| Acyclovir | 143 | $1,425 |
| Dexamethasone | 101 | $1,354 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Des Moines
- Mathew WehbeDes Moines$120K
- Giselle MeryDes Moines$12K
- Emily BrugioniDes Moines$6K
- Millicent AmankwahDes Moines$3K
- Steven HeddingerDes Moines$3K
- Christian SchultheisDes Moines$432
- Matthew HillDes Moines$378
- Magdy ElsawyDes Moines$353
- Robert BehrensDes Moines$345
- Bradley HiattDes Moines$148
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.